OGN: Organon & Co. Stock

by  •  • Comments Off on OGN: Organon & Co. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3,839.90
Enterprise Value ($M) 11,825.90
Book Value ($M) 144.00
Book Value / Share 0.56
Price / Book 26.67
NCAV ($M) -7,503.00
NCAV / Share -29.13
Price / NCAV -0.51

Profitability (mra)
Return on Invested Capital (ROIC) 0.15
Return on Assets (ROA) 0.11
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.21
Current Ratio 1.70

Balance Sheet (mrq) ($M)
Current Assets 4,756.00
Assets 12,752.00
Liabilities 12,259.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-13 13G/A Vanguard Group Inc 11.97 -2.78
2024-02-05 13G/A Mawer Investment Management Ltd. 0.00 -100.00
2024-01-25 13G/A State Street Corp 3.72 -26.09
2024-01-23 13G/A BlackRock, Inc. 13.10 3.38

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-05-03 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P
2024-02-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 509,443 2,001,330 25.46
2025-02-03 812,855 2,804,376 28.99
2025-01-31 679,924 2,240,445 30.35
2025-01-30 378,796 1,383,601 27.38

(click for more detail)

Similar Companies
LLY – Eli Lilly and Company MRK – Merck & Co., Inc.
NUVB – Nuvation Bio Inc. PBH – Prestige Consumer Healthcare Inc.
PFE – Pfizer Inc.


Financial data and stock pages provided by
Fintel.io